Is BioRestorative Therapies Inc (BRTX) overvalued? · rev $401.0K
BioRestorative Therapies Inc (BRTX) is a biotechnology company listed on NASDAQ.
This page asks whether BioRestorative Therapies Inc (BRTX) looks expensive on cached numbers — not a short thesis.
Latest reported BRTX revenue for 2024-12-31 was $401.0K. Net income was -$9.0M. Revenue was up 175.0% from 2023-12-31 to 2024-12-31. BRTX currently screens at market cap $10.2M.
BRTX currently screens at market cap $10.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BRTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BRTX stock page for the full model, not this heading.
Not investment advice.